JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB313095

Alexa Fluor® 568 Anti-Cytokeratin 19 抗体 [EPNCIR127B]

Alexa Fluor® 568 Anti-Cytokeratin 19 antibody [EPNCIR127B]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Cytokeratin 19 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

Krt1-19, Krt19, Cytokeratin-19, Keratin-19, CK-19, K19

関連する標識済み抗体及び組成の異なる製品 (6)

  • Unconjugated

    Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • Carrier free

    Anti-Cytokeratin 19 antibody [EPNCIR127B] - BSA and Azide free

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Cytokeratin 19 antibody [EPNCIR127B]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Cytokeratin 19 antibody [EPNCIR127B]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPNCIR127B

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

下記製品にもご興味をお持ちいただけるかもしれません:

AB252367

Human Cytokeratin 19 ELISA Kit

5

1 Reviews

製品ページを見る
こちらの製品も推奨する理由

この製品は、同様の実験や関連する研究で広く使用されていることから推奨させていただいております。

お客様の実験に適するかご確認いただくため、必ず製品データシートをご確認いただくことをお勧めいたします。ご不明点等ございましたら、テクニカルサポートチームまでお問い合わせください。

style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Cytokeratin 19 (CK19) also known as cytokera­tine 19 keratin 19 (KRT19) or CK19 is a type of intermediate filament found in epithelial cells. It serves as an essential component of the cytoskeleton. CK19 weighs approximately 40 kDa and is broadly expressed in simple epithelial tissues including liver intestine and various glandular epithelial cells. As a cytokeratin marker it often appears in combination with others like cytokeratin 17 in certain tissue types helping to maintain the structural integrity of cells.
Biological function summary

CK19 plays a role in maintaining the cytoskeletal framework that provides mechanical support and helps control cell size and shape. It is not part of a large protein complex but works closely with other cytokeratins to ensure the stability and resilience of epithelial tissues. The A53-B/A22.26 positive staining is often used to confirm its presence in clinical histopathology.

Pathways

CK19 connects to cellular processes especially involving the keratinization and epithelial cell differentiation pathways. It interacts with other cytokeratins including BA16 and KR17 to facilitate these processes. This interaction aids in modulating the dynamics of cytoskeletal rearrangement during cell movement division and differentiation.

CK19 overexpression is linked with certain cancers notably hepatocellular carcinoma and breast cancer. It can serve as a prognostic marker in these diseases often in conjunction with other markers like CK17. The involvement of CK19 in the epithelial-mesenchymal transition (EMT) process connects it to the progression and aggressiveness of tumors facilitated by interactions with proteins involved in EMT pathways.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle (By similarity).
See full target information Krt19
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column
style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com